The main WP 2 objectives are: 1) to collect existing clinical and epidemiological data for the 6 ONTOX case studies; 2) to collect human diseased liver, kidney and brain tissue samples, of relevance for the selected toxicities, for transcriptomic analyses; and 3) to establish qAOP networks for each of the case studies, that will be useful for developing new approach methodologies (NAMs) for chemical risk assessment.

ONTOX largely relies on existing data that must be searched in databases, collected and organized. Moreover, ONTOX forecasts the generation of transcriptomic data from diseased human tissue samples to complement existing data, if data gaps are identified. The collected toxicological information at the tissue, organism and population levels (WP 2) at the molecular and cellular levels (WP 1) will form the solid basis for setting up quantitative adverse outcome pathway (qAOP) networks and ontologies for the selected systemic repeated dose toxicity effects (ONTOX case studies).